trending Market Intelligence /marketintelligence/en/news-insights/trending/0f5S-CgG13rwIb3DhePepg2 content esgSubNav
In This List

US FDA approves Bristol-Myers' Opdivo to treat bladder cancer

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


US FDA approves Bristol-Myers' Opdivo to treat bladder cancer

Bristol-Myers Squibb Co. received U.S. FDA approval for Opdivo as an intravenous treatment for a type of bladder cancer.

The drug will be used to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with such chemotherapy.